Legend Biotech Corporation (LEGN)

Legend Biotech Launches Inaugural ELITE Grant Program to Advance the Next Generation of CAR-T Innovation in Multiple Myeloma

Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) Stock Has Consensus Price Target of $53.14 According to Analysts

Legend Biotech Presents CARVYKTI Data Showing Half of Patients with RRMM Remained Progression-Free and Alive Five Years After a Single Infusion

Legend Biotech taps Novartis veteran Zhang as CEO

Legend Biotech Appoints Ingrid Zhang as Chief Executive Officer

Legend Biotech is tapping a Novartis executive to run the cell-therapy maker, ending a nearly two-month search that began when former CEO Ying Huang resigned in July

Legend Biotech to Present Updated Long-Term and Real-World Evidence from CARVYKTI Clinical Program at the International Myeloma Society Annual Meeting

Legend Biotech to Participate in the Morgan Stanley Global Healthcare Conference

Here Are Wednesday’s Top Wall Street Analyst Research Calls: The Gap, Genmab, Hilton Worldwide, Intuitive Surgical, Marriott International, Merck, Novo Nordisk, Okta, and More

Legend Biotech Corporation (LEGN) Q2 2026 Earnings Call Transcript

Legend Biotech Gains 6% on Q2 Earnings Beat as Adjusted EPS Doubles Consensus

Legend Biotech Q2 Earnings Call Highlights

Legend Biotech (NASDAQ:LEGN) Shares Gap Down After Analyst Downgrade

Legend Biotech Announces CEO Transition

Legend Biotech: Why I'm Ready To Go Long Again